Loading clinical trials...
Loading clinical trials...
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07109154 · Lung Neoplasms
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT06919965 · Non-Muscle Invasive Bladder Neoplasms
NCT03429036 · Hearing Disorder, Oral Mucosal Disease, and more
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
Keck Hospital of USC
Los Angeles, California
LAC&USC Medical Center
Los Angeles, California
USC/Norris Comprehensive Cancer Center / Investigational Drug Services
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions